JP2003528925A - 低温適応型ウマインフルエンザウイルス - Google Patents
低温適応型ウマインフルエンザウイルスInfo
- Publication number
- JP2003528925A JP2003528925A JP2001572128A JP2001572128A JP2003528925A JP 2003528925 A JP2003528925 A JP 2003528925A JP 2001572128 A JP2001572128 A JP 2001572128A JP 2001572128 A JP2001572128 A JP 2001572128A JP 2003528925 A JP2003528925 A JP 2003528925A
- Authority
- JP
- Japan
- Prior art keywords
- virus
- cold
- equine influenza
- influenza virus
- therapeutic composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000283073 Equus caballus Species 0.000 title claims abstract description 279
- 241000712461 unidentified influenza virus Species 0.000 title claims abstract description 247
- 241000700605 Viruses Species 0.000 claims abstract description 208
- 239000000203 mixture Substances 0.000 claims abstract description 148
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 139
- 241001465754 Metazoa Species 0.000 claims abstract description 136
- 238000000034 method Methods 0.000 claims abstract description 89
- 241000712431 Influenza A virus Species 0.000 claims abstract description 67
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 52
- 201000010099 disease Diseases 0.000 claims abstract description 44
- 230000002238 attenuated effect Effects 0.000 claims abstract description 18
- 206010022000 influenza Diseases 0.000 claims description 41
- 208000015181 infectious disease Diseases 0.000 claims description 24
- 230000003612 virological effect Effects 0.000 claims description 22
- 208000023504 respiratory system disease Diseases 0.000 claims description 21
- 206010039101 Rhinorrhoea Diseases 0.000 claims description 17
- 208000010753 nasal discharge Diseases 0.000 claims description 17
- 230000006978 adaptation Effects 0.000 claims description 16
- 230000002829 reductive effect Effects 0.000 claims description 13
- 230000002452 interceptive effect Effects 0.000 claims description 11
- 208000035143 Bacterial infection Diseases 0.000 claims description 8
- 206010037660 Pyrexia Diseases 0.000 claims description 8
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 8
- 208000036142 Viral infection Diseases 0.000 claims description 6
- 230000004044 response Effects 0.000 claims description 6
- 238000011282 treatment Methods 0.000 claims description 6
- 230000009385 viral infection Effects 0.000 claims description 4
- 238000012549 training Methods 0.000 claims description 3
- 230000000840 anti-viral effect Effects 0.000 claims description 2
- 230000000241 respiratory effect Effects 0.000 claims description 2
- 241000283086 Equidae Species 0.000 abstract description 49
- 239000012678 infectious agent Substances 0.000 abstract description 7
- 210000004027 cell Anatomy 0.000 description 84
- 238000002255 vaccination Methods 0.000 description 55
- 235000013601 eggs Nutrition 0.000 description 54
- 210000001519 tissue Anatomy 0.000 description 34
- 230000035772 mutation Effects 0.000 description 31
- 241000287828 Gallus gallus Species 0.000 description 28
- 230000012010 growth Effects 0.000 description 20
- 108090000623 proteins and genes Proteins 0.000 description 19
- 101710154606 Hemagglutinin Proteins 0.000 description 14
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 14
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 14
- 101710176177 Protein A56 Proteins 0.000 description 14
- 230000035945 sensitivity Effects 0.000 description 14
- 229960005486 vaccine Drugs 0.000 description 13
- 210000002966 serum Anatomy 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 108010067390 Viral Proteins Proteins 0.000 description 11
- 238000004458 analytical method Methods 0.000 description 11
- 238000003556 assay Methods 0.000 description 11
- 239000000185 hemagglutinin Substances 0.000 description 10
- 238000001243 protein synthesis Methods 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 230000014616 translation Effects 0.000 description 10
- 208000003322 Coinfection Diseases 0.000 description 9
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 9
- 230000035931 haemagglutination Effects 0.000 description 9
- 239000002953 phosphate buffered saline Substances 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 9
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 8
- 206010020751 Hypersensitivity Diseases 0.000 description 8
- 210000001161 mammalian embryo Anatomy 0.000 description 8
- 239000003381 stabilizer Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 7
- 230000028327 secretion Effects 0.000 description 7
- OCKGFTQIICXDQW-ZEQRLZLVSA-N 5-[(1r)-1-hydroxy-2-[4-[(2r)-2-hydroxy-2-(4-methyl-1-oxo-3h-2-benzofuran-5-yl)ethyl]piperazin-1-yl]ethyl]-4-methyl-3h-2-benzofuran-1-one Chemical compound C1=C2C(=O)OCC2=C(C)C([C@@H](O)CN2CCN(CC2)C[C@H](O)C2=CC=C3C(=O)OCC3=C2C)=C1 OCKGFTQIICXDQW-ZEQRLZLVSA-N 0.000 description 6
- 102000011931 Nucleoproteins Human genes 0.000 description 6
- 108010061100 Nucleoproteins Proteins 0.000 description 6
- 239000002671 adjuvant Substances 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 239000002773 nucleotide Substances 0.000 description 6
- 125000003729 nucleotide group Chemical group 0.000 description 6
- 230000007505 plaque formation Effects 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 230000006798 recombination Effects 0.000 description 6
- 210000002345 respiratory system Anatomy 0.000 description 6
- 230000006656 viral protein synthesis Effects 0.000 description 6
- 101150118742 NP gene Proteins 0.000 description 5
- 208000030961 allergic reaction Diseases 0.000 description 5
- 239000003242 anti bacterial agent Substances 0.000 description 5
- 229940088710 antibiotic agent Drugs 0.000 description 5
- 230000014509 gene expression Effects 0.000 description 5
- 230000028993 immune response Effects 0.000 description 5
- 230000036039 immunity Effects 0.000 description 5
- 230000002458 infectious effect Effects 0.000 description 5
- 208000037797 influenza A Diseases 0.000 description 5
- 238000002955 isolation Methods 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 238000005215 recombination Methods 0.000 description 5
- 230000002441 reversible effect Effects 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 238000010561 standard procedure Methods 0.000 description 5
- 239000003104 tissue culture media Substances 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 101000633984 Homo sapiens Influenza virus NS1A-binding protein Proteins 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 239000013553 cell monolayer Substances 0.000 description 4
- 230000000875 corresponding effect Effects 0.000 description 4
- 230000003111 delayed effect Effects 0.000 description 4
- 244000052769 pathogen Species 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- 230000029812 viral genome replication Effects 0.000 description 4
- 235000006576 Althaea officinalis Nutrition 0.000 description 3
- 241000271566 Aves Species 0.000 description 3
- 206010011224 Cough Diseases 0.000 description 3
- 241000230501 Equine herpesvirus sp. Species 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 101150039660 HA gene Proteins 0.000 description 3
- 102100029241 Influenza virus NS1A-binding protein Human genes 0.000 description 3
- 102000004142 Trypsin Human genes 0.000 description 3
- 108090000631 Trypsin Proteins 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000012790 confirmation Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000015788 innate immune response Effects 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 230000000366 juvenile effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000006199 nebulizer Substances 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000000644 propagated effect Effects 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 206010041232 sneezing Diseases 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- 102000002322 Egg Proteins Human genes 0.000 description 2
- 108010000912 Egg Proteins Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241001551462 Influenza A virus (A/equine/Kentucky/1/1991(H3N8)) Species 0.000 description 2
- 101150080862 NA gene Proteins 0.000 description 2
- 102000005348 Neuraminidase Human genes 0.000 description 2
- 108010006232 Neuraminidase Proteins 0.000 description 2
- 108090001074 Nucleocapsid Proteins Proteins 0.000 description 2
- 101150105115 PA gene Proteins 0.000 description 2
- 101150103639 PB1 gene Proteins 0.000 description 2
- 101150030427 PB2 gene Proteins 0.000 description 2
- 208000037656 Respiratory Sounds Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000282898 Sus scrofa Species 0.000 description 2
- 230000003044 adaptive effect Effects 0.000 description 2
- 230000004596 appetite loss Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 210000003711 chorioallantoic membrane Anatomy 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 210000003278 egg shell Anatomy 0.000 description 2
- 210000002257 embryonic structure Anatomy 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- 210000003292 kidney cell Anatomy 0.000 description 2
- 208000019017 loss of appetite Diseases 0.000 description 2
- 235000021266 loss of appetite Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000001331 nose Anatomy 0.000 description 2
- 238000009021 pre-vaccination Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000001902 propagating effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101710117545 C protein Proteins 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000283153 Cetacea Species 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 229920004934 Dacron® Polymers 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 241000710945 Eastern equine encephalitis virus Species 0.000 description 1
- 241000713730 Equine infectious anemia virus Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100027612 Kallikrein-11 Human genes 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 description 1
- 241000282339 Mustela Species 0.000 description 1
- MQUQNUAYKLCRME-INIZCTEOSA-N N-tosyl-L-phenylalanyl chloromethyl ketone Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N[C@H](C(=O)CCl)CC1=CC=CC=C1 MQUQNUAYKLCRME-INIZCTEOSA-N 0.000 description 1
- 101150076514 NS gene Proteins 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 241000283216 Phocidae Species 0.000 description 1
- 235000014676 Phragmites communis Nutrition 0.000 description 1
- 206010039424 Salivary hypersecretion Diseases 0.000 description 1
- 208000008630 Sialorrhea Diseases 0.000 description 1
- 241000194048 Streptococcus equi Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 101710152431 Trypsin-like protease Proteins 0.000 description 1
- 241000710959 Venezuelan equine encephalitis virus Species 0.000 description 1
- 241000710951 Western equine encephalitis virus Species 0.000 description 1
- 206010047924 Wheezing Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 239000003855 balanced salt solution Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 230000001427 coherent effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 239000011121 hardwood Substances 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 210000002850 nasal mucosa Anatomy 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 239000005020 polyethylene terephthalate Substances 0.000 description 1
- 229940021993 prophylactic vaccine Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 230000000601 reactogenic effect Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000036387 respiratory rate Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000006163 transport media Substances 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 210000005189 upper gingiva Anatomy 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 230000007485 viral shedding Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16161—Methods of inactivation or attenuation
- C12N2760/16164—Methods of inactivation or attenuation by serial passage
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Pulmonology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19432500P | 2000-04-03 | 2000-04-03 | |
| US60/194,325 | 2000-04-03 | ||
| PCT/US2001/008968 WO2001074386A2 (en) | 2000-04-03 | 2001-03-21 | Cold-adapted equine influenza viruses |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003528925A true JP2003528925A (ja) | 2003-09-30 |
| JP2003528925A5 JP2003528925A5 (enExample) | 2008-04-24 |
Family
ID=22717146
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001572128A Pending JP2003528925A (ja) | 2000-04-03 | 2001-03-21 | 低温適応型ウマインフルエンザウイルス |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US7029903B2 (enExample) |
| EP (1) | EP1267920B1 (enExample) |
| JP (1) | JP2003528925A (enExample) |
| AT (1) | ATE350056T1 (enExample) |
| AU (2) | AU2001249300B2 (enExample) |
| CA (1) | CA2403979A1 (enExample) |
| DE (1) | DE60125736D1 (enExample) |
| WO (1) | WO2001074386A2 (enExample) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007534664A (ja) * | 2004-01-23 | 2007-11-29 | バヴァリアン・ノルディック・アクティーゼルスカブ | 弱毒化ウサギ粘液腫ウイルスに基づく単一類属免疫誘導剤 |
| JP2015518047A (ja) * | 2012-05-31 | 2015-06-25 | ゾエティス・エルエルシー | Ｂ．ブロンキセプチカ（Ｂ．Ｂｒｏｎｃｈｉｓｅｐｔｉｃａ）感染から保護するためのイヌ呼吸器コロナウイルスでのワクチン接種 |
| JP2016025857A (ja) * | 2015-08-07 | 2016-02-12 | ウィスコンシン アルムニ リサーチ ファンデイション | Ｈ３型ウマａ型インフルエンザウイルス |
| US9814770B2 (en) | 2005-01-11 | 2017-11-14 | Wisconsin Alumni Research Foundation | H3 influenza A virus |
| JP2018088928A (ja) * | 2018-02-13 | 2018-06-14 | ウィスコンシン アルムニ リサーチ ファンデイション | Ｈ３型ウマａ型インフルエンザウイルス |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11865172B2 (en) | 2005-04-21 | 2024-01-09 | University Of Florida Research Foundation, Inc. | Materials and methods for respiratory disease control in canines |
| US7959929B2 (en) | 2005-04-21 | 2011-06-14 | University Of Florida Research Foundation, Inc. | Materials and methods for respiratory disease control in canines |
| CN102459578A (zh) | 2009-01-30 | 2012-05-16 | 俄克拉荷马州大学评议会 | 基于在北美狗中循环的犬瘟热病毒的免疫原性组合物、疫苗和诊断方法 |
| CN107375919B (zh) | 2009-03-27 | 2022-07-29 | 台湾地区“中央研究院” | 抗病毒免疫的方法和组合物 |
| ES2687702T3 (es) * | 2010-03-10 | 2018-10-26 | Intervet International B.V. | Método para protección contra enfermedad causada por patógenos secundarios |
| TWI537385B (zh) * | 2010-11-04 | 2016-06-11 | 中央研究院 | 產生具簡單醣基化之表面蛋白質之病毒顆粒的方法 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000009702A1 (en) * | 1998-08-13 | 2000-02-24 | The University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Cold-adapted equine influenza viruses |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3518347A (en) | 1965-05-28 | 1970-06-30 | Inst Microbiologie Et D Hygien | Vaccine for equine influenza |
| US3992522A (en) | 1973-01-24 | 1976-11-16 | The United States Of America As Represented By The Department Of Health, Education And Welfare | Temperature-sensitive recombinant mutant viruses and a process for producing same |
| US4683137A (en) | 1982-04-16 | 1987-07-28 | Cornell Research Foundation, Inc. | Temperature sensitive reassortant viruses and a vaccine against equine influenza |
| AU558483B2 (en) | 1982-04-16 | 1987-01-29 | Cornell Research Foundation Inc. | Temperature sensitive reassortant viruses and a vaccine against equine influenza |
| GB8300467D0 (en) | 1983-01-08 | 1983-02-09 | Wellcome Found | Equine influenza |
| US4631191A (en) | 1985-06-20 | 1986-12-23 | Biotechnology Research Partners, Ltd. | Methods and compositions useful in preventing equine influenza |
| US4920213A (en) | 1985-06-20 | 1990-04-24 | Biotechnology Research Partners, Ltd. | Method and compositions useful in preventing equine influenza |
| US5149531A (en) | 1990-06-27 | 1992-09-22 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Method of using cold-adapted live influenza virus vaccine as an antiviral agent against influenza |
| IL105456A (en) | 1992-04-21 | 1996-12-05 | American Home Prod | Vaccines of attenuated respiratory syncytial virus |
| US5690937A (en) | 1995-06-05 | 1997-11-25 | Aviron | Temperature sensitive clustered changed-to-alanine mutants of influenza virus PB2 gene |
-
2001
- 2001-03-21 US US10/239,972 patent/US7029903B2/en not_active Expired - Lifetime
- 2001-03-21 JP JP2001572128A patent/JP2003528925A/ja active Pending
- 2001-03-21 DE DE60125736T patent/DE60125736D1/de not_active Expired - Lifetime
- 2001-03-21 AT AT01922507T patent/ATE350056T1/de not_active IP Right Cessation
- 2001-03-21 WO PCT/US2001/008968 patent/WO2001074386A2/en not_active Ceased
- 2001-03-21 AU AU2001249300A patent/AU2001249300B2/en not_active Expired
- 2001-03-21 CA CA002403979A patent/CA2403979A1/en not_active Abandoned
- 2001-03-21 EP EP01922507A patent/EP1267920B1/en not_active Expired - Lifetime
- 2001-03-21 AU AU4930001A patent/AU4930001A/xx active Pending
-
2006
- 2006-01-17 US US11/332,989 patent/US20060121521A1/en not_active Abandoned
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000009702A1 (en) * | 1998-08-13 | 2000-02-24 | The University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Cold-adapted equine influenza viruses |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007534664A (ja) * | 2004-01-23 | 2007-11-29 | バヴァリアン・ノルディック・アクティーゼルスカブ | 弱毒化ウサギ粘液腫ウイルスに基づく単一類属免疫誘導剤 |
| JP4846598B2 (ja) * | 2004-01-23 | 2011-12-28 | バヴァリアン・ノルディック・アクティーゼルスカブ | 弱毒化ウサギ粘液腫ウイルスに基づくモノ非特異的免疫誘導剤 |
| US9814770B2 (en) | 2005-01-11 | 2017-11-14 | Wisconsin Alumni Research Foundation | H3 influenza A virus |
| US10034932B2 (en) | 2005-01-11 | 2018-07-31 | Wisconsin Alumni Research Foundation (Warf) | H3 influenza A virus |
| US10369212B2 (en) | 2005-01-11 | 2019-08-06 | Wisconsin Alumni Research Foundation (Warf) | H3 influenza A virus |
| JP2015518047A (ja) * | 2012-05-31 | 2015-06-25 | ゾエティス・エルエルシー | Ｂ．ブロンキセプチカ（Ｂ．Ｂｒｏｎｃｈｉｓｅｐｔｉｃａ）感染から保護するためのイヌ呼吸器コロナウイルスでのワクチン接種 |
| JP2016025857A (ja) * | 2015-08-07 | 2016-02-12 | ウィスコンシン アルムニ リサーチ ファンデイション | Ｈ３型ウマａ型インフルエンザウイルス |
| JP2018088928A (ja) * | 2018-02-13 | 2018-06-14 | ウィスコンシン アルムニ リサーチ ファンデイション | Ｈ３型ウマａ型インフルエンザウイルス |
Also Published As
| Publication number | Publication date |
|---|---|
| US20060121521A1 (en) | 2006-06-08 |
| WO2001074386A2 (en) | 2001-10-11 |
| ATE350056T1 (de) | 2007-01-15 |
| US7029903B2 (en) | 2006-04-18 |
| WO2001074386A3 (en) | 2002-05-23 |
| EP1267920B1 (en) | 2007-01-03 |
| AU2001249300B2 (en) | 2006-02-16 |
| AU4930001A (en) | 2001-10-15 |
| US20040223980A1 (en) | 2004-11-11 |
| CA2403979A1 (en) | 2001-10-11 |
| DE60125736D1 (de) | 2007-02-15 |
| EP1267920A2 (en) | 2003-01-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5261338B2 (ja) | 低温適応性ウマインフルエンザウィルス | |
| US7438919B2 (en) | Cold-adapted equine influenza viruses | |
| US7399477B2 (en) | Cold-adapted equine influenza viruses | |
| De Jong et al. | Influenza virus: a master of metamorphosis | |
| JP2002522078A5 (enExample) | ||
| CN101514334B (zh) | 鸡传染性支气管炎病毒弱毒疫苗株及其应用 | |
| US8282937B2 (en) | Cold-adapted (CA) reassortant influenza virus | |
| TW201701900A (zh) | 二價豬流感病毒疫苗 | |
| JP2003528925A (ja) | 低温適応型ウマインフルエンザウイルス | |
| AU2001249300A1 (en) | Cold-adapted equine influenza viruses | |
| US20010051161A1 (en) | Cold-adapted equine influenza viruses |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080303 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080303 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20101208 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20110719 |